POTS and ADHD: The Dopamine-Norepinephrine Overlap

For many patients, a POTS diagnosis arrives alongside — or after — a lifetime of ADHD symptoms. The overlap is not coincidental. Both conditions involve dysfunction in the same neurotransmitter systems, particularly norepinephrine and dopamine, and the autonomic nervous system plays a central role in both. Understanding this connection is not just academically interesting — it has direct implications for how both conditions should be treated, and why certain medications can help or harm depending on the individual.

How Common Is the Overlap?

Research suggests that ADHD is significantly more prevalent in people with POTS than in the general population. A 2021 survey study published in the journal Frontiers in Neuroscience found that approximately 30–40% of POTS patients reported a co-diagnosis of ADHD, compared to roughly 5–10% in the general adult population. Clinicians who specialize in dysautonomia frequently observe this pattern in practice, and many POTS specialists now routinely screen for ADHD during initial evaluations.

The reverse is also true: people with ADHD who have never been evaluated for POTS may be experiencing unrecognized orthostatic intolerance. Symptoms such as difficulty concentrating, restlessness, fatigue, and emotional dysregulation — all hallmarks of ADHD — are also core features of POTS, particularly when blood flow to the brain is reduced upon standing. This creates a diagnostic challenge: are the cognitive symptoms primarily neurological (ADHD), cardiovascular-autonomic (POTS), or both?

The Shared Neurobiology

The connection between POTS and ADHD runs through the catecholamine system — the network of neurotransmitters that includes norepinephrine (also called noradrenaline) and dopamine. Both neurotransmitters are essential for attention, executive function, emotional regulation, and cardiovascular control.

Norepinephrine is the primary neurotransmitter of the sympathetic nervous system. It regulates heart rate, blood vessel tone, and blood pressure responses to positional changes. In POTS, norepinephrine signaling is often dysregulated — either deficient in neuropathic POTS (where the peripheral nerves that release norepinephrine are damaged) or excessive in hyperadrenergic POTS (where norepinephrine levels spike dramatically upon standing). In ADHD, norepinephrine deficiency in the prefrontal cortex impairs working memory, impulse control, and sustained attention.

Dopamine plays a complementary role. In the prefrontal cortex, dopamine regulates the "signal-to-noise ratio" of neural firing — too little dopamine makes it difficult to filter out irrelevant stimuli and maintain focus. In the cardiovascular system, dopamine influences renal blood flow and sodium retention, both of which affect blood volume and orthostatic tolerance.

This shared neurochemistry explains why the two conditions so frequently co-occur, and why treatments targeting one system often affect the other.

Why POTS Looks Like ADHD (and Vice Versa)

One of the most clinically important aspects of this overlap is symptom mimicry. Reduced cerebral blood flow — which occurs in POTS when blood pools in the lower extremities upon standing — produces cognitive symptoms that are virtually indistinguishable from ADHD: difficulty concentrating, forgetfulness, distractibility, impulsivity, and emotional reactivity. This phenomenon is sometimes called "brain fog," but in the context of POTS, it has a specific hemodynamic mechanism.

A patient who has been managing ADHD for years may find that their symptoms worsen dramatically when POTS develops or worsens — not because their ADHD has changed, but because the cerebral hypoperfusion of POTS is layering additional cognitive impairment on top of their baseline. Conversely, a patient whose POTS is well-controlled with salt loading, hydration, and compression may find that their apparent ADHD symptoms improve significantly, sometimes to the point where stimulant medication is no longer needed at the same dose.

This does not mean ADHD is "just POTS" in disguise. Many patients have both conditions independently, and each requires its own treatment. But it does mean that treating POTS aggressively can meaningfully reduce cognitive symptoms, and that clinicians should not assume all cognitive dysfunction in a POTS patient is attributable to ADHD alone.

Medication Interactions: What Helps and What Hurts

The medication landscape for patients with both POTS and ADHD is complex, because the same drugs that treat one condition can worsen the other — or, in some cases, treat both simultaneously.

Stimulants (amphetamines and methylphenidate): These are the first-line treatments for ADHD and work primarily by increasing dopamine and norepinephrine availability in the prefrontal cortex. For POTS patients, the cardiovascular effects are a significant concern. Stimulants increase heart rate and blood pressure, which can worsen tachycardia in POTS. However, in some patients — particularly those with hypovolemic or neuropathic POTS — the vasoconstricting effect of norepinephrine reuptake inhibition can actually improve orthostatic tolerance by increasing peripheral vascular resistance. The net effect depends heavily on the POTS subtype and the individual patient's cardiovascular profile. Patients with hyperadrenergic POTS, who already have elevated norepinephrine, are generally poor candidates for stimulants.

Atomoxetine (Strattera): A selective norepinephrine reuptake inhibitor (SNRI) approved for ADHD, atomoxetine has been studied in POTS and found to improve orthostatic tolerance in some patients by increasing norepinephrine-mediated vasoconstriction. A small but notable study found that atomoxetine reduced the heart rate increase upon standing in POTS patients. For patients with both conditions, atomoxetine represents a potentially dual-purpose treatment worth discussing with a specialist.

Guanfacine and clonidine: These alpha-2 adrenergic agonists are used for ADHD (particularly in children and adolescents) and work by reducing norepinephrine activity in the prefrontal cortex, paradoxically improving focus. In POTS, particularly hyperadrenergic POTS, these same drugs are used to reduce the excessive sympathetic activation that drives tachycardia and hypertension upon standing. For patients with hyperadrenergic POTS and ADHD, guanfacine may be the most logical choice — treating both conditions through the same mechanism.

Beta-blockers: Commonly prescribed for POTS to reduce heart rate, beta-blockers can worsen ADHD symptoms by reducing norepinephrine activity systemically, including in the brain. Patients on beta-blockers often report increased brain fog, fatigue, and difficulty concentrating — symptoms that can be mistaken for worsening ADHD.

Practical Recommendations for Patients

If you have both POTS and ADHD — or suspect you might — the following approach is worth discussing with your medical team:

Treat POTS first, then reassess ADHD. Before adjusting ADHD medications, optimize POTS management with salt loading, hydration, compression, and any appropriate medications. Many patients find that cognitive symptoms improve substantially once POTS is better controlled, and ADHD medication doses can sometimes be reduced.

Know your POTS subtype. The safest and most effective ADHD treatment depends heavily on whether you have neuropathic, hyperadrenergic, hypovolemic, or deconditioned POTS. A cardiologist or autonomic specialist who understands both conditions is essential.

Monitor heart rate with stimulants. If you are prescribed stimulants, track your resting and standing heart rate carefully. A wearable device can help identify whether stimulants are worsening orthostatic tachycardia.

Consider atomoxetine or guanfacine. For patients with hyperadrenergic POTS, these non-stimulant ADHD medications may offer the best balance of cognitive benefit and cardiovascular safety.

Advocate for integrated care. Most cardiologists and neurologists who treat POTS are not ADHD specialists, and most psychiatrists who treat ADHD are not familiar with POTS. Patients often need to be the bridge between their providers, sharing information about both conditions and their interactions.

The Emotional Dimension

Living with both POTS and ADHD presents unique emotional challenges. ADHD already carries significant stigma — the perception that it represents laziness or lack of willpower rather than a neurobiological condition. Adding POTS, an invisible illness that is frequently dismissed by medical providers, compounds this burden. Many patients describe years of being told their symptoms are anxiety, depression, or "just stress" before receiving accurate diagnoses for either condition.

The cognitive symptoms of POTS — brain fog, memory lapses, difficulty processing information — can also be misattributed to ADHD, leading to medication escalation when the real solution is better POTS management. Conversely, untreated ADHD can make POTS management far harder: remembering to take medications, maintaining hydration schedules, tracking symptoms, and advocating in medical appointments all require the executive function that ADHD impairs.

Recognizing the bidirectional relationship between these two conditions — and finding providers who understand both — is one of the most important steps a patient can take toward meaningful improvement in quality of life.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.